DexCom
DXCM
418 hedge funds and large institutions have $13.3B invested in DexCom in 2019 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 150 increasing their positions, 149 reducing their positions, and 91 closing their positions.
26% more capital invested
Capital invested by funds: $10.6B → $13.3B (+$2.72B)
7% more call options, than puts
Call options by funds: $68M | Put options by funds: $63.5M
1% more repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 149
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
4.71% less ownership
Funds ownership: 394.52% → 389.81% (-4.7%)
9% less funds holding
Funds holding: 457 → 418 (-39)
36% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 91
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$537M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$153M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$132M |
| 4 |
Jennison Associates
New York
|
+$119M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$117M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$214M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$123M |
| 3 |
Renaissance Technologies
New York
|
-$121M |
| 4 |
HM
HealthCor Management
New York
|
-$87M |
| 5 |
MSE
MUFG Securities EMEA
London,
United Kingdom
|
-$69.5M |
DXCM Hedge Fund Activity: Q2 2019 in Review
418 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q2 2019, worth a combined $13.3B — up 26% from $10.6B a quarter earlier.
Sellers outnumbered buyers: 91 funds closed out of DXCM and 58 opened new positions — a net loss of 33 holders — while 149 trimmed existing stakes and 150 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $537M. The largest seller was Morgan Stanley, cutting an estimated $214M.
- 418 institutional investors held DexCom (DXCM) as of Q2 2019, down from 457 in Q1 2019.
- Funds reported $13.3B of DexCom stock for Q2 2019, up 26% quarter-over-quarter.
- 58 funds opened new DexCom positions in Q2 2019 and 91 closed out, a net change of -33 holders.
- The largest DexCom buyer in Q2 2019 was T. Rowe Price Associates, an estimated $537M added.
- The largest DexCom seller in Q2 2019 was Morgan Stanley, an estimated $214M sold.
Based on aggregated 13F filings for Q2 2019.